Efficacy of Liposomal Bupivacaine and Bupivacaine Hydrochloride vs Bupivacaine Hydrochloride Alone as a Periarticular Anesthetic for Patients Undergoing Knee Replacement

医学 布比卡因 麻醉 可视模拟标度 不利影响 随机对照试验 局部麻醉剂 骨关节炎 外科 患者满意度 内科学 病理 替代医学
作者
Thomas W. Hamilton,Ruth Knight,Jamie R. Stokes,Ines Rombach,Cushla Cooper,Loretta Davies,Susan Dutton,Karen Barker,Jonathan Cook,Sarah E Lamb,David W. Murray,Lisa Poulton,Ariel Wang,Louise Strickland,Bernard van Duren,José Leal,David Beard,Hemant Pandit,Kirti Mohalkar,Simon Jones
出处
期刊:JAMA Surgery [American Medical Association]
卷期号:157 (6): 481-481 被引量:22
标识
DOI:10.1001/jamasurg.2022.0713
摘要

Importance

More than half of patients who undergo knee replacement surgery report substantial acute postoperative pain.

Objective

To evaluate the efficacy and cost-effectiveness of periarticular liposomal bupivacaine for recovery and pain management after knee replacement.

Design, Setting, and Participants

This multicenter, patient-blinded, pragmatic, randomized clinical superiority trial involved 533 participants at 11 institutions within the National Health Service in England. Adults undergoing primary unilateral knee replacement for symptomatic end-stage osteoarthritis were enrolled between March 29, 2018, and February 29, 2020, and followed up for 1 year after surgery. Follow-up was completed March 1, 2021. A per-protocol analysis for each coprimary outcome was performed in addition to the main intention-to-treat analysis.

Interventions

Two hundred sixty-six milligrams of liposomal bupivacaine admixed with 100 mg of bupivacaine hydrochloride compared with 100 mg of bupivacaine hydrochloride alone (control) administered by periarticular injection at the time of surgery.

Main Outcome and Measures

The coprimary outcomes were Quality of Recovery 40 (QoR-40) score at 72 hours and pain visual analog scale (VAS) score area under the curve (AUC) from 6 to 72 hours. Secondary outcomes included QoR-40 and mean pain VAS at days 0 (evening of surgery), 1, 2, and 3; cumulative opioid consumption for 72 hours; functional outcomes and quality of life at 6 weeks, 6 months, and 1 year; and cost-effectiveness for 1 year. Adverse events and serious adverse events up to 12 months after randomization were also assessed.

Results

Among the 533 participants included in the analysis, the mean (SD) age was 69.0 (9.7) years; 287 patients were women (53.8%) and 246 were men (46.2%). Baseline characteristics were balanced between study groups. There was no difference between the liposomal bupivacaine and control groups in QoR-40 score at 72 hours (adjusted mean difference, 0.54 [97.5% CI, −2.05 to 3.13];P = .64) or the pain VAS score AUC at 6 to 72 hours (−21.5 [97.5% CI, −46.8 to 3.8];P = .06). Analyses of pain VAS and QoR-40 scores demonstrated only 1 statistically significant difference, with the liposomal bupivacaine arm having lower pain scores the evening of surgery (adjusted difference −0.54 [97.5% CI, −1.07 to −0.02];P = .02). No difference in cumulative opioid consumption and functional outcomes was detected. Liposomal bupivacaine was not cost-effective compared with the control treatment. No difference in adverse or serious adverse events was found between the liposomal bupivacaine and control groups.

Conclusions and Relevance

This study found no difference in postoperative recovery or pain associated with the use of periarticular liposomal bupivacaine compared with bupivacaine hydrochloride alone in patients who underwent knee replacement surgery.

Trial Registration

isrctn.com Identifier:ISRCTN54191675
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
sysi完成签到 ,获得积分10
14秒前
绿波电龙完成签到,获得积分10
15秒前
18秒前
ZZzz完成签到 ,获得积分10
19秒前
wujiwuhui发布了新的文献求助10
23秒前
25秒前
梦梦的小可爱完成签到 ,获得积分10
25秒前
xinjie发布了新的文献求助10
28秒前
30秒前
蛋花肉圆汤完成签到,获得积分10
30秒前
羞涩的文轩完成签到 ,获得积分10
31秒前
36秒前
37秒前
北城完成签到 ,获得积分10
39秒前
量子星尘发布了新的文献求助10
39秒前
42秒前
爱听歌电灯胆完成签到 ,获得积分10
42秒前
不爱吃西葫芦完成签到 ,获得积分10
43秒前
申燕婷完成签到 ,获得积分10
44秒前
橙子完成签到 ,获得积分10
46秒前
ruochenzu发布了新的文献求助10
46秒前
fusheng完成签到 ,获得积分10
55秒前
浮生完成签到 ,获得积分10
1分钟前
xinjie完成签到,获得积分10
1分钟前
Will完成签到,获得积分10
1分钟前
cuddly完成签到 ,获得积分10
1分钟前
掉头发的小白完成签到,获得积分10
1分钟前
不想看文献完成签到 ,获得积分10
1分钟前
1分钟前
当女遇到乔完成签到 ,获得积分10
1分钟前
独行者完成签到,获得积分10
1分钟前
眼睛大的电脑完成签到,获得积分10
1分钟前
1分钟前
敏敏发布了新的文献求助10
1分钟前
木木完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
JamesPei应助科研通管家采纳,获得10
1分钟前
彭于晏应助科研通管家采纳,获得10
1分钟前
如意2023完成签到 ,获得积分10
1分钟前
fomo完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022